Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Depreciation & Amortization (CF): 2010-2024

Historic Depreciation & Amortization (CF) for Capricor Therapeutics (CAPR) over the last 15 years, with Dec 2024 value amounting to $1.4 million.

  • Capricor Therapeutics' Depreciation & Amortization (CF) rose 36.98% to $494,726 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 29.85%. This contributed to the annual value of $1.4 million for FY2024, which is 33.34% up from last year.
  • Per Capricor Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $1.4 million for FY2024, which was up 33.34% from $1.1 million recorded in FY2023.
  • Capricor Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $1.4 million for FY2024, and its period low was $143,890 during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.1 million (2023), whereas its average is $1.0 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Depreciation & Amortization (CF) fell by 16.32% in 2020, and later soared by 116.99% in 2022.
  • Yearly analysis of 5 years shows Capricor Therapeutics' Depreciation & Amortization (CF) stood at $143,890 in 2020, then soared by 70.75% to $245,697 in 2021, then surged by 116.99% to $533,131 in 2022, then soared by 100.49% to $1.1 million in 2023, then soared by 33.34% to $1.4 million in 2024.